A case series of lacosamide as adjunctive therapy in refractory sleep-related hypermotor epilepsy (previously nocturnal frontal lobe epilepsy).

Abstract

The aim of this study was to evaluate the efficacy and tolerability of open-label lacosamide in patients with refractory sleep-related hypermotor epilepsy. The study was a case review of eight patients with refractory sleep-related hypermotor epilepsy treated with lacosamide. Seizure diaries compared the mean baseline seizure frequency with the most recent 3 months of follow-up. Five (62.5%) patients were responders, defined as ≥50% reduction in seizure frequency, over a mean duration of exposure of 21.5 months. The mean maintenance dose of lacosamide was 400 mg/day. No-one reported worsening of seizures. Lacosamide was well tolerated with initial fatigue being the main side-effect. Lacosamide is a potentially efficacious adjunctive therapy in patients with refractory sleep-related hypermotor epilepsy. A double-blind placebo-controlled study would determine its efficacy.

• Authors: Shanika R Samarasekera, Samuel F Berkovic, Ingrid E Scheffer
• Journal: Journal of sleep research (J Sleep Res) Vol. 27 Issue 5 Pg. e12669 (10 2018) ISSN: 1365-2869 [Electronic] England
• PMID: 29479765 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2018 European Sleep Research Society.

Chemical References

• Anticonvulsants
• Lacosamide

Topics

• Adult
• Anticonvulsants (pharmacology, therapeutic use)
• Epilepsies, Partial (drug therapy)
• Female
• Humans
• Lacosamide (pharmacology, therapeutic use)
• Male
• Middle Aged
• Treatment Outcome
• Young Adult